Evidence map›Paper›PMID 34597618›Full record

ArticleJournal of immunological methods2021

Broad immunophenotyping of the murine brain tumor microenvironment.

W H Tomaszewski, J Waibl-Polania, A M Miggelbrink, M A Chakraborty, P E Fecci, J H Sampson, M D Gunn

Abstract read
In one paragraph

Article in Journal of immunological methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. IL-7-mediated expansion of autologous lymphocytes increases CD8bioRxiv : the preprint server for biology · 2025
    Article
  2. Article
  3. CD8Nature cancer · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

W H TomaszewskiDuke School of Medicine, Department of Immunology, United States of America.
J Waibl-PolaniaDuke School of Medicine, Department of Pathology, United States of America.
A M MiggelbrinkDuke School of Medicine, Department of Pathology, United States of America.
M A ChakrabortyDuke School of Medicine, Department of Biomedical Engineering, United States of America.
P E FecciDuke School or Medicine, Department of Neurosurgery, United States of America.
J H SampsonDuke School or Medicine, Department of Neurosurgery, United States of America.
M D GunnDuke School of Medicine, Department of Cardiology, United States of America. Electronic address: michael.gunn@duke.edu.

Funding

Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 AntibodyP50CA190991 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2014 to 2023
$20.8M
Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent GlioblastomaP01CA225622 · NCI · DUKE UNIVERSITY · PI GUNN, MICHAEL D · 2018 to 2022
$12.2M
Human EGFRvIII-specific BiTE for the treatment of GlioblastomaU01NS090284 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2015 to 2019
$5.2M
Basic Immunology Training ProgramT32AI052077 · NIAID · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2002 to 2024
$4.2M
Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine EfficacyR01CA235612 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2019 to 2022
$2.0M
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor TherapyR01NS099463 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2017 to 2021
$1.7M
Clinical Neuroimmunology of Vaccines in Brain TumorsR01NS116888 · NINDS · DUKE UNIVERSITY · PI LI, QIJING, SAMPSON, JOHN H. · 2021 to 2022
$802k
NCI NIH HHS P01 CA225622NCI NIH HHS P50 CA190991NCI NIH HHS R01 CA235612NIAID NIH HHS T32 AI052077NINDS NIH HHS R01 NS099463NINDS NIH HHS R01 NS116888NINDS NIH HHS U01 NS090284
6 · The paper itself

Abstract

Here we present a 14-color flow cytometry panel for the evaluation of 13 myeloid and lymphoid populations within murine glioblastoma samples. Reagents, processing protocols, and downstream analyses were thoroughly validated and optimized to resolve the following populations: T cells (CD4, CD8, CD3), B cells (B220), NK cells (NK1.1), neutrophils (Ly6G), classical and non-classical monocytes (Ly6c, CD43), macrophages (F4/80, CD11b), microglia (CD45-lo, CD11b), and dendritic cells (DCs) (CD11c, MHC class II). In addition, this panel leaves Alexa Fluor 488/FITC open for the inclusion of fluorescent reporters or congenic marker staining.

Indexed as

ImmunophenotypingAnimalsBrain NeoplasmsMiceMice, Inbred C57BLTumor MicroenvironmentGlioblastomaMulticolor flow cytometryPreclinicalTumor microenvironmentUnbiased cell classification

Identifiers

PMID34597618
PMCPMC8608727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.